Phase 1 dose escalation for VIP943 - first antibody-drug conjugate (ADC) from VersAptx™, versatile and adaptable, next-generation bioconjugation platform -…
Vancouver, British Columbia--(Newsfile Corp. - November 14, 2023) - Defence Therapeutics Inc. (CSE: DTC) (OTC Pink: DTCFF) (FSE: DTC) ("Defence"…
LUND, SE / ACCESSWIRE / November 14, 2023 / Spago Nanomedical (STO:SPAGO.ST) (FRA:7UX.F) In accordance with the instructions to the…
Long-term relationship will focus on the potential for new advancements to expand patient and clinician access and transform the approach…
MONTREAL, QC / ACCESSWIRE / November 13, 2023 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and…
– FDA feedback indicates Company’s CMC plans are in alignment with FDA’s requirements and expectations towards a BLA – –…
NORCROSS, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target…
PASADENA, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW),…
Completed enrollment of 380 patients in pivotal Phase 3 trial of lead therapeutic cancer vaccine, IO102-IO103 in combination with KEYTRUDA®…
KNOXVILLE, TN, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided updated data from an ongoing Phase 1…